

# Hepatocyte-based in vitro model for drug-induced cholestasis

*Commonly used acronym: DICI-MODEL*

*Created on: 28-08-2019 - Last modified on: 08-11-2019*

## Contact person

Pieter Annaert

## Organisation

**Name of the organisation** Katholieke Universiteit Leuven (KUL)

**Department** Pharmaceutical and Pharmacological Sciences

**Country** Belgium

**Geographical Area** Flemish Region

## SCOPE OF THE METHOD

<b>The Method relates to</b>	Human health
<b>The Method is situated in</b>	Translational - Applied Research
<b>Type of method</b>	In vitro - Ex vivo
<b>Specify the type of cells/tissues/organs</b>	Human liver tissue (from resections during surgery)

## DESCRIPTION

### Method keywords

bile acids

sandwich-cultured human hepatocytes

in vitro model

## **Scientific area keywords**

Hepatotoxicity

Drug-induced liver injury (DILI)

Drug-induced cholestasis

## **Method description**

Sandwich-cultured hepatocytes are exposed to test compounds (e.g. drug candidates) or known hepatotoxicants (as controls) both in the absence and in the presence of a mixture of physiologically relevant bile acids. After 24h, decreased hepatocyte viability and functionality in the presence of bile acids is expressed as a drug-induced cholestasis index (DICI) value. DICI values < 0.8 are indicative of possible cholestatic liabilities and a safety margin can be calculated provided *in vivo* therapeutic exposure data (or estimates) are available.

## **Lab equipment**

Biosafety cabinet ;

Plate reader (absorbance) ;

Incubator.

## **Method status**

Internally validated

Published in peer reviewed journal

## **PROS, CONS & FUTURE POTENTIAL**

### **Advantages**

Early detection of cholestasis potential of medicines and environmental toxicants.

### **Challenges**

Availability and characterisation of plateable human hepatocytes.

### **Modifications**

Additional endpoints (ATP instead of urea, bile acid profiles) are under development.

## Future & Other applications

Could extrapolate concept of co-incubation with endogenous compounds to other organs / tissues.

## REFERENCES, ASSOCIATED DOCUMENTS AND OTHER INFORMATION

### References

Chatterjee S, Richert L, Augustijns P, Annaert P. Hepatocyte-based in vitro model for assessment of drug-induced cholestasis. *Toxicol Appl Pharmacol*. 2014 Jan 1;274(1):124-36. doi: 10.1016/j.taap.2013.10.032. Epub 2013 Nov 7. PubMed PMID: 24211272.

Chatterjee S, Richert L, Augustijns P, Annaert P. Hepatocyte-based in vitro model for assessment of drug-induced cholestasis. *Toxicol Appl Pharmacol*. 2014 Jan 1;274(1):124-36. doi: 10.1016/j.taap.2013.10.032. Epub 2013 Nov 7. PubMed PMID: 24211272.

Oorts M, Baze A, Bachellier P, Heyd B, Zacharias T, Annaert P, Richert L. Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes. *Toxicol In Vitro*. 2016 Aug;34:179-186. doi: 10.1016/j.tiv.2016.03.008. Epub 2016 Apr 2. PubMed PMID: 27046439.

### Links

[Link to initial publication on this topic](#)

Coordinated by



Financed by

